Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AerovectRx, an aerosol drug delivery and therapeutics company, has appointed David Johnston as its new CEO. Dr Johnson succeeds Ed Cannon, who becomes executive chairman of the board.
Subscribe to our email newsletter
Most recently Dr Johnson was senior vice president of R&D at Nektar Therapeutics. Prior to Nektar, Dr Johnson was chief development officer for Control Delivery Systems.
Dr Johnston earned his bachelor’s and doctorate degrees in chemistry from St Andrews University (Scotland) and completed postdoctoral training at the Max Planck Institute for Medicinal Research (Heidelberg, Germany).
Dr Cannon said: “David is the most qualified person to take the company to the next level and create significant value. His successful experience in the inhaled drug delivery market and broader knowledge of drug development will be invaluable as we launch our initial therapeutic AeroCell-based products.”